相关实验视频

Updated: May 15, 2025

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Published on: June 28, 2021

封装伊塔西提尼布的小麦芽聚氨酸纳米颗粒准并抑制促炎性slan+单细胞

Karen Alvarez¹, Cristian A Anacona¹, Esneyder Ruiz Agudelo²

¹Cellular Immunology and Immunogenetics Group (GICIG), Faculty of Medicine, University of Antioquia, Medellin, Colombia.

Nanomedicine (London, England)

|April 28, 2025

概括

用伊塔西提尼布纳米颗粒向促炎性6-sulfoLacNAc (slan) +单细胞显示出治疗诸如系统性红斑狼 (SLE) 等自身免疫性疾病的前景. 这种新的方法可以选择性地抑制这些特定免疫细胞中的关键炎症途径.

科学领域:

免疫学免疫学免疫学
纳米医学是一种纳米医学.
药理学药理学是指药理学的学科.

背景情况:

6-sulfoLacNAc (slan) +单细胞与自身免疫性疾病 (如全身性红斑狼 (SLE)) 的亲炎症过程有关.
准这些特定的单细胞子集为新的治疗干预提供了潜在的战略.

研究的目的:

评估通过小麦芽聚氨酸功能化纳米颗粒 (WGA/F127/PNPs) 输送的伊塔西丁 (ITA) 的治疗潜力.
评估这种向传递系统在抑制JAK-STAT通路的有效性,特别是在slan+单细胞内.

主要方法:

用ITA装载的WGA/F127/PNPs的制备和表征.
纳米粒子结合和内部化在白细胞子集的流细胞计分析,包括slan+和slan-单细胞.
从健康对照组和SLE患者的外周血液样本中评估slan+单细胞表型和功能.

主要成果:

WGA/F127/PNPs被slan+单细胞有效地内化,但不是slan-单细胞.
装有ITA的纳米粒子显著降低了IFN-γ刺激的slan+单细胞中的促炎标志物 (HLA-DR,CD69,CD86),STAT1酸化和细胞因子产生.
与健康对照组相比,SLE患者的slan+单细胞数量减少.

结论:

WGA/F127/PNPs代表了一种有前途的药物输送系统,专门针对和抑制促炎性瘦+单细胞.
这种细胞特异性方法在治疗系统性红斑狼和其他自身免疫性疾病方面具有治疗潜力.

关键词:

在PLGA纳米粒子中.较少的单细胞.亚努斯酶抑制剂的使用这是一种狼,狼.小麦芽聚合素是小麦芽聚合素的组成部分.

更多相关视频

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling

Published on: July 26, 2017

Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity

Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity

Published on: January 7, 2019

相关概念视频

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...